1. Home
  2. RGT vs BMEA Comparison

RGT vs BMEA Comparison

Compare RGT & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Royce Global Value Trust Inc.

RGT

Royce Global Value Trust Inc.

HOLD

Current Price

$13.57

Market Cap

95.0M

Sector

Finance

ML Signal

HOLD

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$1.52

Market Cap

107.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RGT
BMEA
Founded
1986
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
95.0M
107.7M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
RGT
BMEA
Price
$13.57
$1.52
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$8.86
AVG Volume (30 Days)
13.4K
1.3M
Earning Date
01-01-0001
05-04-2026
Dividend Yield
1.43%
N/A
EPS Growth
N/A
69.19
EPS
0.92
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$14.67
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.00
$0.87
52 Week High
$14.99
$3.07

Technical Indicators

Market Signals
Indicator
RGT
BMEA
Relative Strength Index (RSI) 45.85 63.59
Support Level $12.50 $1.22
Resistance Level $14.95 $1.66
Average True Range (ATR) 0.20 0.13
MACD 0.01 0.04
Stochastic Oscillator 50.94 90.38

Price Performance

Historical Comparison
RGT
BMEA

About RGT Royce Global Value Trust Inc.

Royce Global Value Trust Inc is a diversified closed-end investment company. The fund spreads its investments across diversified sectors such as information technology, consumer discretionary, health care, materials, consumer staples, and energy. Geographically, it has presence in the region of the United Kingdom, Japan, the United States, Canada, France, Hong Kong, and Germany.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

Share on Social Networks: